Polycystic ovary syndrome (PCOS) is a hormonal endocrine disorder which affects women of age 15 to 49 years. This disease which leads to formation of lumps on ovaries creating insufficiency of ovulation hormone in female. PCOS can also cause missed or irregular menstrual periods and an irregular periods that can lead to infertility and development of cysts in ovaries.
According to study, “Polycystic Ovarian Syndrome Treatment Market by Drug Class (Insulin Sensitizing Agent, Oral Contraceptive, Antiandrogens, Anti-Obesity Drugs, and Others), and Distribution Channel (Hospital Pharmacy, Drug Store & Retail Pharmacy, and Online Providers): Global Opportunity Analysis and Industry Forecast, 2019-2026”. Some of the key companies operating in the global polycystic ovarian syndrome treatment market are Allergan Plc., Bayer AG, Bristol-Myers Squibb Company, SANOFI, AstraZeneca Plc., Johnson and Johnson, Novartis AG, Mylan N.V., Pfizer Inc., and Teva Pharmaceutical Industries. The companies are increasingly investing to create initiatives for increasing awareness levels among the women about the feminine hygiene in the developing countries over Asia Pacific and the Middle East and Africa regions.
Based on drug class, polycystic ovarian syndrome treatment market is segmented into insulin sensitizing agent, antiandrogens, oral contraceptive, anti-obesity drugs, and others. Insulin sensitizing agent segment dominates the market owing to significant adoption of insulin sensitizing agents over the first line treatment for managing PCOS. Based on surgery type, market is segmented into laparoscopic ovarian drilling and ovarian wedge resection. In addition, based on distribution channel, market is segmented into drug stores & retail pharmacies, hospital pharmacies, and online providers. The online providers segment is projected to exhibit significant growth due to increase in awareness of online providers, growth in preference for online purchasing of drugs over the traditional methods, and rise in number of internet users during the forecast period.
The polycystic ovarian syndrome treatment market is driven by increase in prevalence of PCOS, followed by surge in popularity of combination therapy, rise in awareness among the patient population about PCOS, growth in technological advancements for detection of PCOS, rise in demand for PCOS medication, and easy accessibility to PCOS therapeutics. However, unknown etiology & pathophysiology of PCOS and lack of approved therapeutics may impact the market. Moreover, higher number of unmet needs for treatment of PCOS is a key opportunity for market.
Based on geography, the North-American is a leading region in global polycystic ovarian syndrome treatment market owing to presence of multiple local and global biopharmaceutical companies in the region. Whereas, the Asian-Pacific and European regions are estimated to exhibit substantial growth rate due to rise in adoption of polycystic ovarian syndrome treatment products over the forecast period. In upcoming years, it is expected that future of the market will be optimistic caused by growth in awareness about polycystic ovarian syndrome treatment coupled with rise in healthcare reforms during the forecast period. The global polycystic ovarian syndrome treatment market was valued at US $2,902 million in 2018, and is projected to reach US $4,184 million by 2026, registering a CAGR of 4.7% from 2019-2026.
For More Information, Click on the Link Below:-
Ankur Gupta, Head Marketing & Communications